Synaptogenix: At Alzheimer's Association, to Highlight Bryostatin Restoring Cognitive Function Above Baseline

 Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimer's Association International Conference ("AAIC"), which will be held online and in-person July 26-30, 2021.

The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy."

"Bryostatin improved cognition in patients with advanced Alzheimer's disease significantly above their baseline levels in recently completed data analyses that consolidated all pre-specified patients under identical protocol conditions in our two Phase 2 pilot trials," commented Dr. Daniel Alkon, Synaptogenix's President and Chief Scientific Officer. "We believe the results provide evidence of significant AD patient cognitive improvement – with potential clinically meaningful benefit – at a level not observed with the randomized placebo control patients."

https://www.prnewswire.com/news-releases/synaptogenix-to-present-data-at-alzheimers-association-international-conference-2021-highlighting-bryostatin-restores-cognitive-function-above-baseline-301333425.html